Abstract
Ceramide is a bioactive molecule involved in numerous cell signaling pathways that are associated with cell cycle control, differentiation, senescence and apoptosis. Although substantial knowledge about ceramide-regulated pathways has accumulated in the past decade, molecular mechanisms of ceramide action remain poorly understood, primarily due to limited information about ceramide-binding proteins. In the present study, we used affinity purification with a synthetic biotin-conjugated C6-ceramide analogue and LC-MS/MS to identify potential ceramide-interacting proteins in D6P2T Schwannoma cells. The purification resulted in identification of 97 unique proteins. The identified proteins are involved in various cellular processes, including apoptosis, cellular stress, cell cycle, cell differentiation, signaling, transcription, translation, protein biogenesis, metabolism and transport.
Ceramide belongs to a family of biologically active lipid molecule and is comprised of a long-chain sphingoid base and an N-acyl chain. Ceramide is involved in signal transduction mechanisms that control the cell cycle, as well as differentiation and apoptosis [1–3]. The signaling and biological responses of ceramide depend upon their subcellular localization, intracellular lipid traffic, and the rate of flux through the network of sphingoid metabolic pathways [3]. Cellular ceramide can change in response to various stimuli, including physiological elements such as growth factors, hormones, and cytokines, as well as xenobiotics such as chemotherapeutic agents. Ceramide is a common intermediary metabolite in several metabolic pathways, and its concentration is controlled by many enzymes involved in de novo synthesis or hydrolysis of ceramide, or conversion of ceramide to complex sphingolipids [4–9].
Numerous studies showed that an increase in ceramide was associated with programmed cell death [1, 3, 10]. Similarly, treatment with proapoptotic agents induced accumulation of ceramide, which implicated this lipid in cellular responses to these agents [7]. For instance, several anticancer agents such as daunorubicin, camptothecin, fludarabine, and etoposide stimulate ceramide synthesis in cancerous cells [11]. Because of its apoptosis-inducing effects in cancer cells, ceramide has been termed the “tumor suppressor lipid” [12].
In the last decade ceramide has been extensively studied as potential chemopreventive molecules because they are intimately involved in the regulation of cancer cell growth, differentiation, senescence, and cell death [1, 7, 13]. In many studies, cell-permeable ceramide analogues (C2- or C6-ceramide) were shown to have activity against a variety of cancer cell lines. In addition, blocking ceramide clearance by inhibiting specific enzymes can elevate endogenous ceramide, leading to increased cytotoxic effects of chemotherapeutic agents in various cancer cells [1]. Ceramide treatment can also limit tumor growth in vivo as shown in a mouse model of breast adenocarcinoma [13]. In many of these studies, however, the direct targets of ceramide and downstream pathways have yet to be established. Currently, a limited number of proteins are known to directly interact with ceramide, including c-Raf [14], kinase suppressor of RAS (KSR) [15], cathepsin D [16, 17], protein kinase C ζ (PKC-ζ) [18], ceramide transfer protein CERT [19] and inhibitor 2 of protein phosphatase 2A (I2PP2A) [20]. It is imperative to identify all ceramide-interacting proteins to fully delineate ceramide-mediated signaling pathways and to design ceramide-based therapeutics in cancer treatment. To this end, we have utilized affinity purification with a synthetic biotin-conjugated ceramide analogue and LC-MS/MS to identify potential ceramide-interacting proteins in D6P2T Schwannoma cells. The proteins we identified are involved in apoptosis, cellular stress, cell cycle, cell differentiation, signaling, transcription, translation, protein biogenesis, metabolism and transport.
Rat Schwannoma-derived D6P2T cells were purchased from ATCC (Manassas, VA) and grown in DMEM containing 10% FBS. Biotin-conjugated D-erythro-C6-ceramide analogue (B-C6-Cer) was prepared by the method of Ong and Brady [21]. Briefly, D-erythro-sphingosine (Avanti Polar Lipids) was condensed with N-hydroxysuccinimide ester of (+)-biotin (Sigma-Aldrich) in anhydrous dimethylformamide at room temperature for 24 hr. The pure (+)-2-N-biotinyl-D-erythro-sphingosine was obtained at a yield of 72% as a white microcrystalline powder after silica gel column purification following recrystallization from actetone. The following characteristics were obtained: TLC Rf (CHCl3-CH3OH, 50:8, v/v) = 0.45; [α]23D = +41° (c = 0.25, CHCl3-CH3OH, 9:1, v/v); [α]22365 = +124° (c = 0.25, CHCl3-CH3OH, 9:1, v/v).
For affinity purification, cells were harvested at ~60–70% confluency. B-C6-Cer-interacting proteins were isolated using the Dynabeads® Streptavidin Kit (Invitrogen). Approximately 2 × 106 cells were harvested by trypsin-EDTA treatment, washed with PBS, and disrupted in a lysis buffer containing 10 mM Tris-HCl (pH 8.0); 150 mM NaCl; 1 mM EDTA; 0.1% SDS; 1% sodium deoxycholate; 1% Triton X-100; and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) for 1 hr at room temperature. To exclude non-specific interaction with biotin or the beads, cell lysates were first incubated with biotin-bound beads on an orbital shaker for 1 hr at RT, and bound proteins were discarded. Subsequently, samples were incubated with B-C6-Cer beads for 1 hr at RT on an orbital shaker. The beads were washed with lysis buffer 5 times and boiled in Laemmli buffer. Proteins bound to B-C6-Cer beads were resolved on 12% SDS PAGE and stained with Imperial Protein Stain (Thermo Fisher, Rockford, IL). Control experiments were performed in parallel with biotin-bound beads. The proteins were resolved in molecular weight range of 20–150 kDa (Fig. 1). Each lane was cut into pieces and processed for LC-MS/MS analysis.
Fig. 1.
Separation of biotin C6-ceramide-interacting proteins in D6P2T cells by SDS PAGE. The gel was stained with Imperial Protein Stain and bands were excised and subjected to LC-MS/MS analyses. The control sample was obtained with biotin-bound beads.
Gel pieces were placed in Eppendorf tubes and washed with 50 mM ammonium bicarbonate for 10 min, and destained twice with 25 mM ammonium bicarbonate in 50% acetonitrile for 15 min. The gel pieces were dehydrated by immersion in 100% acetonitrile for 15 min and vacuum-dried in a SpeedVac. Dried gel pieces were treated with proteomics grade trypsin (Sigma-Aldrich) at 37 °C overnight. The samples were briefly spun, and supernatants were transferred to clean dry Eppendorf tubes. Peptides were further extracted from the gel once with 25 mM ammonium bicarbonate for 20 min, followed by three washes with 5% formic acid in 50% acetonitrile for 20 min. Pooled supernatants were dried in a SpeedVac to ~2 μL. Prior to LC-MS/MS analysis the samples were reconstituted with 10 μl of 0.2% formic acid in 2% acetonitrile.
Trypsin-digested samples were analyzed by LC-MS/MS. A linear ion trap mass spectrometer (LTQ, Thermo Finnigan) was interfaced with an LC Packings Nano LC system with a 75-μm i.d. C-18 reversed-phase LC column (Microtech Scientific). Peptides were fractionated by a gradient of 2–60% acetonitrile in 0.2% formic acid. Data Dependant Analysis was utilized on the LTQ to perform MS/MS on all ions above an ion count of 1000. Dynamic Exclusion was set to exclude ions from MS/MS selection for 3 min after being selected 2 times in a 30-sec window.
The MS/MS data were searched against the NCBI Rat Genome Database using the Thermo Finnigan Bioworks 3.3.1 SP1 software. Variable modifications of methionine oxidation were considered. Protein identification must meet the minimum criteria of a Protein Probability of 1.0 E-3 or better and have an Xcorr vs charge state >1.5, 2.0, 2.5 for +1, +2, and +3 ions, respectively, with at least 3 unique peptides matching the protein, and a good match for at least 4 consecutive y or b ion series from the MS/MS spectra. Non-specific proteins identified in control samples were excluded from the list of identified proteins.
Overall, 97 unique proteins were identified in this study (Table 1, Supplemental Table S1). The detailed peptide data for identified proteins are provided as Supplemental Table S2. All of the available proteomic data are deposited in the PRIDE proteomics identification database (accession numbers 19308–19311). The identified proteins were annotated using the Gene Ontology Slimmer tool on the AmiGO Gene Ontology database (http://amigo.geneontology.org). The detailed distribution of proteins based on biological process, cellular component and molecular function are depicted in Fig. 2. The complete lists of proteins under each classification are provided in Supplemental Table S1.
TABLE 1.
B-C6-Cer interacting protein in D6P2T Schwann cellsi dentified by LC-MS/MS
| S. No | Protein | Accession No.a) |
|---|---|---|
| 1 | Adaptor protein complex AP-2, alpha 2 subunit | 162138932 |
| 2 | ADP-ribosyltransferase 1 | 6978455 |
| 3 | Arginyl-tRNA synthetase | 158631214 |
| 4 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma subunit | 39930503 |
| 5 | ATP-binding cassette, sub-family F (GCN20), member 2 | 157821181 |
| 6 | Brix domain containing 1 | 157822643 |
| 7 | Casein kinase II, alpha 2, polypeptide | 157817807 |
| 8 | Chaperonin containing TCP1, subunit 3 (gamma) | 40018616 |
| 9 | Chaperonin subunit 4 (delta) | 33414505 |
| 10 | Chaperonin subunit 6a (zeta) | 76253725 |
| 11 | Chaperonin subunit 7 (eta) | 157819651 |
| 12 | Coatomer protein complex, subunit beta 1 | 18158449 |
| 13 | Coatomer protein complex, subunit gamma | 73532768 |
| 14 | Cullin associated and neddylation disassociated 1 | 16758920 |
| 15 | Cytochrome c oxidase subunit II | 110189718 |
| 16 | Cytoplasmic FMR1 interacting protein 1 | 157822937 |
| 17 | DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked | 157823027 |
| 18 | DEK oncogene (DNA binding) | 51948482 |
| 19 | Developmentally regulated GTP binding protein 1 | 57528300 |
| 20 | Dynein cytoplasmic 1 heavy chain 1 | 148491097 |
| 21 | Eukaryotic translation initiation factor 3, subunit 6 | 58865556 |
| 22 | Fatty acid synthase | 8394158 |
| 23 | Glycosyltransferase 25 domain containing 1 | 157823499 |
| 24 | Guanylate nucleotide binding protein 2 | 19424350 |
| 25 | High density lipoprotein binding protein | 162287194 |
| 26 | Hydroxyacyl-Coenzyme A dehydrogenase type II | 13994225 |
| 27 | Hydroxysteroid (17-beta) dehydrogenase 4 | 162287198 |
| 28 | Hypothetical protein LOC294718 | 166158346 |
| 29 | Hypothetical protein LOC497813 | 66730357 |
| 30 | Hypothetical protein LOC498736 | 157819845 |
| 31 | Kinesin family member 5B | 83776543 |
| 32 | Ly1 antibody reactive clone | 58865392 |
| 33 | Metadherin | 19173758 |
| 34 | Myosin IC | 124107592 |
| 35 | Myosin IE | 27465533 |
| 36 | Nascent-polypeptide-associated complex alpha polypeptide | 157786942 |
| 37 | Neural precursor cell expressed, developmentally down-regulated gene 4 | 158186672 |
| 38 | NMDA receptor-regulated gene 1 | 157818303 |
| 39 | Nucleolar protein 5A | 71143106 |
| 40 | Nucleolar protein family 6 (RNA-associated) | 157817474 |
| 41 | Phosphatidylinositol-4-phosphate 5-kinase, type II, gamma | 158534075 |
| 42 | Pleckstrin homology domain containing, family C (with FERM domain) member 1 | 58865400 |
| 43 | Polypyrimidine tract binding protein 1 isoform b | 13487910 |
| 44 | PREDICTED: similar to 40S ribosomal protein S2 | 62655115 |
| 45 | PREDICTED: similar to 40S ribosomal protein S9 | 27665858 |
| 46 | PREDICTED: similar to 60S ribosomal protein L9 | 109477682 |
| 47 | PREDICTED: similar to ARP3 actin-related protein 3 homolog B | 109472893 |
| 48 | PREDICTED: similar to DNA replication licensing factor MCM4 (CDC21 homolog) (P1-CDC21) | 34870013 |
| 49 | PREDICTED: similar to eukaryotic translation initiation factor 3, subunit 8 | 109462864 |
| 50 | PREDICTED: similar to eukaryotic translation initiation factor 4, gamma 1 isoform a | 109494661 |
| 51 | PREDICTED: similar to eukaryotic translation initiation factor 4A, isoform 1 | 109479422 |
| 52 | PREDICTED: similar to FRG1 protein (FSHD region gene 1 protein) | 109504227 |
| 53 | PREDICTED: similar to GCN1 general control of amino-acid synthesis 1-like 1 isoform 2 | 109496005 |
| 54 | PREDICTED: similar to glutaminyl-tRNA synthetase | 109483957 |
| 55 | PREDICTED: similar to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) | 109481109 |
| 56 | PREDICTED: similar to Histone deacetylase 2 (HD2) | 62666128 |
| 57 | PREDICTED: similar to isoleucine-tRNA synthetase | 109505545 |
| 58 | PREDICTED: similar to Laminin alpha-2 chain precursor (Laminin M chain) (Merosin heavy chain) | 109460394 |
| 59 | PREDICTED: similar to proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 | 109469981 |
| 60 | PREDICTED: similar to Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 (DEAH box protein 15) | 109500663 |
| 61 | PREDICTED: similar to RAB6A, member RAS oncogene family | 109462512 |
| 62 | PREDICTED: similar to ribosomal protein S8 | 109506240 |
| 63 | PREDICTED: similar to solute carrier family 25, member 5 | 62652442 |
| 64 | PREDICTED: similar to SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a4 | 109484265 |
| 65 | PREDICTED: similar to T-complex protein 1 subunit alpha (TCP-1-alpha) (CCT-alpha) | 109473894 |
| 66 | Programmed cell death protein 11 | 158186708 |
| 67 | Prohibitin 2 | 61556754 |
| 68 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 | 56605666 |
| 69 | Proteasome 26S non-ATPase subunit 12 | 54400716 |
| 70 | Protein disulfide isomerase-associated 4 | 16758712 |
| 71 | Pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase) | 157823607 |
| 72 | RAB33B, member of RAS oncogene family | 157822117 |
| 73 | Radixin | 56799432 |
| 74 | Ribophorin I | 6981486 |
| 75 | Ribosomal protein L13 | 13592055 |
| 76 | Ribosomal protein L13A | 77404207 |
| 77 | Ribosomal protein L18 | 13592057 |
| 78 | Ribosomal protein L5 | 13592051 |
| 79 | Ribosomal protein L7a | 167466288 |
| 80 | Ribosomal protein L8 | 78214309 |
| 81 | RNA binding motif protein 25 | 157823201 |
| 82 | SEC23A (S. cerevisiae) (predicted) | 157786714 |
| 83 | Serine/threonine kinase 2 | 132626321 |
| 84 | Small inducible cytokine subfamily E, member 1 | 75832035 |
| 85 | Solute carrier family 25, member 4 | 32189355 |
| 86 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 | 157817975 |
| 87 | T-complex protein 1 | 6981642 |
| 88 | Topoisomerase (DNA) 2 alpha | 38259192 |
| 89 | Transportin 3 | 157819279 |
| 90 | Tropomyosin 1, alpha isoform h | 78000201 |
| 91 | Tropomyosin 3, gamma isoform 2 | 29336093 |
| 92 | Tubulin, alpha 1A | 11560133 |
| 93 | Tubulin, beta 6 | 71043680 |
| 94 | Tumor rejection antigen gp96 (predicted) | 58865966 |
| 95 | UDP-glucose dehydrogenase | 13786146 |
| 96 | Valyl-tRNA synthetase 2 | 158186770 |
| 97 | Zuotin related factor 2 | 158138509 |
Accession numbers are from NCBI database
Fig. 2.
Gene Ontology annotations of identified biotin C6-ceramide interacting proteins in D6P2T cells. Gene Ontology analysis was carried out using the GO Slimmer tool in the AmiGO Gene Ontology database. The 97 proteins were categorized based on biological processes (A), molecular function (B), or subcellular localization (C).
The cellular locations and functions of the 97 proteins are diverse. As expected, there are proteins involved in apoptosis and cell cycle control. The largest cluster of proteins, however, is involved in gene expression and protein synthesis, including ribosomal proteins, tRNA synthetases, and eukaryotic translation initiation factors. For example, two subunits each of eukaryotic initiation factor 3 and eukaryotic initiation factor 4 were identified in this study. These proteins may participate in the previously reported inhibition of protein synthesis by ceramide [22]. Another large cluster of proteins is involved in metabolic processes, suggesting a possibility that ceramide regulates metabolic rates during cell proliferation, apoptosis, and stress response. There are several proteins involved in protein folding, suggesting a novel role for ceramide in this process. It should be noted that not all 97 proteins would directly bind B-C6-Cer. Some of them would indirectly interact with B-C6-Cer through complexation with other proteins. Further studies are warranted to refine this list to identify direct targets of ceramide.
Interestingly, known ceramide-binding proteins (c-Raf, KSR, cathepsin D, PKC-ζ, CERT, I2PP2A) were not identified in this study, indicating that these proteins do not interact with B-C6-Cer under our experimental conditions. It is possible that the acyl chain lengths and lipid environment were not optimal for these proteins, and/or biotin moiety interferes with the binding. Using alternative conditions and different ceramide analogues would likely identify additional ceramide-interacting proteins.
Supplementary Material
Acknowledgments
All the available proteomic data set are deposited in the PRIDE proteomics identification database (accession numbers 19308-19311). This work was supported by National Institutes of Health grant NS060807 (to HH).
References
- 1.Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4:604–616. doi: 10.1038/nrc1411. [DOI] [PubMed] [Google Scholar]
- 2.Struckhoff AP, Bittman R, Burow ME, Clejan S, et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharm Exp Ther. 2004;309:523–532. doi: 10.1124/jpet.103.062760. [DOI] [PubMed] [Google Scholar]
- 3.Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139–150. doi: 10.1038/nrm2329. [DOI] [PubMed] [Google Scholar]
- 4.Chalfant CE, Rathman K, Pinkerman RL, Wood RE, et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. J Biol Chem. 2002;277:12587–12595. doi: 10.1074/jbc.M112010200. [DOI] [PubMed] [Google Scholar]
- 5.Perry DK, Carton J, Shah AK, Meredith F, et al. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J Biol Chem. 2000;275:9078–9084. doi: 10.1074/jbc.275.12.9078. [DOI] [PubMed] [Google Scholar]
- 6.Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol. 1999;15:541–546. doi: 10.3892/ijo.15.3.541. [DOI] [PubMed] [Google Scholar]
- 7.Radin NS. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J. 2003;371:243–256. doi: 10.1042/BJ20021878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism--a strategy for overcoming drug resistance. J Natl Cancer Inst. 2001;93:347–357. doi: 10.1093/jnci/93.5.347. [DOI] [PubMed] [Google Scholar]
- 9.Strum JC, Small GW, Pauig SB, Daniel LW. 1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem. 1994;269:15493–15497. [PubMed] [Google Scholar]
- 10.Lemonnier LA, Dillehay DL, Vespremi MJ, Abrams J, et al. Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch Biochem Biophys. 2003;419:129–138. doi: 10.1016/j.abb.2003.08.023. [DOI] [PubMed] [Google Scholar]
- 11.Huang WC, Chen CL, Lin YS, Lin CF. Apoptotic sphingolipid ceramide in cancer therapy. J Lipids. 2011;2011:565316. doi: 10.1155/2011/565316. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hannun YA. Sphingolipid second messengers: tumor suppressor lipids. Adv Exp Med Biol. 1997;400A:305–312. doi: 10.1007/978-1-4615-5325-0_43. [DOI] [PubMed] [Google Scholar]
- 13.Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res. 2005;11:3465–3474. doi: 10.1158/1078-0432.CCR-04-1770. [DOI] [PubMed] [Google Scholar]
- 14.Huwiler A, Brunner J, Hummel R, Vervoordeldonk M, et al. Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proc Natl Acad Sci USA. 1996;93:6959–6963. doi: 10.1073/pnas.93.14.6959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Zhang Y, Yao B, Delikat S, Bayoumy S, et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell. 1997;89:63–72. doi: 10.1016/s0092-8674(00)80183-x. [DOI] [PubMed] [Google Scholar]
- 16.Abbott DE, Margaryan NV, Jeruss J, Khan S, et al. Reevaluating Cathepsin D as a biomarker for breast cancer: Serum activity levels versus histopathology. Cancer Biol Ther. 2010;9:23–30. doi: 10.4161/cbt.9.1.10378. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J. 1996;15:3861–3870. [PMC free article] [PubMed] [Google Scholar]
- 18.Bourbon NA, Yun J, Kester M. Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex. J Biol Chem. 2000;275:35617–35623. doi: 10.1074/jbc.M007346200. [DOI] [PubMed] [Google Scholar]
- 19.Hanada K, Kumagai K, Yasuda S, Miura Y, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature. 2003;426:803–809. doi: 10.1038/nature02188. [DOI] [PubMed] [Google Scholar]
- 20.Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 2009;23:751–763. doi: 10.1096/fj.08-120550. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ong DE, Brady RN. Synthesis of ceramides using N -hydroxysuccinimide esters. J Lipid Res. 1972;13:819–822. [PubMed] [Google Scholar]
- 22.Ruvolo PP, Gao F, Blalock WL, Deng X, May WS. Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J Biol Chem. 2001;276:11754–11758. doi: 10.1074/jbc.M011400200. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.


